
Sign up to save your podcasts
Or


We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.
By Retina Synthesis4.5
88 ratings
We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.

43 Listeners

18 Listeners

100 Listeners

111,948 Listeners

56,508 Listeners

5 Listeners

9,532 Listeners

11 Listeners

47,654 Listeners

50 Listeners

11 Listeners

466 Listeners

19 Listeners

0 Listeners